Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 4,000 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Theravance Biopharma Trading Up 8.6 %

TBPH stock traded up $0.77 during midday trading on Wednesday, hitting $9.68. The stock had a trading volume of 285,946 shares, compared to its average volume of 346,350. The firm has a market cap of $473.56 million, a P/E ratio of -9.92 and a beta of 0.25. The business has a fifty day moving average price of $8.32 and a two-hundred day moving average price of $8.68. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same quarter last year, the company earned ($0.17) EPS. On average, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in Theravance Biopharma in the 3rd quarter worth $60,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in Theravance Biopharma in the second quarter worth about $108,000. Ballentine Partners LLC acquired a new position in shares of Theravance Biopharma during the third quarter worth $104,000. Finally, XTX Topco Ltd acquired a new stake in shares of Theravance Biopharma during the second quarter worth $129,000. 99.10% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on TBPH. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. TD Cowen lowered their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Theravance Biopharma has an average rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.